PE20081398A1 - Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1) - Google Patents
Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1)Info
- Publication number
- PE20081398A1 PE20081398A1 PE2008000023A PE2008000023A PE20081398A1 PE 20081398 A1 PE20081398 A1 PE 20081398A1 PE 2008000023 A PE2008000023 A PE 2008000023A PE 2008000023 A PE2008000023 A PE 2008000023A PE 20081398 A1 PE20081398 A1 PE 20081398A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- sphingosine
- agonists
- oxadiazol
- indol
- Prior art date
Links
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title abstract 5
- 239000000556 agonist Substances 0.000 title abstract 2
- 150000004866 oxadiazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- -1 1-METHYLETHYL Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 abstract 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE OXADIAZOL DE FORMULA (I) DONDE R5, R6 Y R2 SON CADA UNO H O UN COMPUESTO DE FORMULA (a) EN DONDE A ES FENILO O UN ANILLO HETEROARILICO DE 5 O 6 MIEMBROS; R1 ES H O HASTA TRES SUSTITUYENTES SELECCIONADOS DE HALOGENO, ALQUILO(C1-C6), CICLOALQUILO(C3-C6), ALCOXI(C1-C6), TRIFLUOROMETOXI, ENTRE OTROS; R7 ES H O HALOGENO; Z ES ALQUILO(C1-C4) OPCIONALMENTE INTERRUMPIDO CON N U O, Y OPCIONALMENTE SUSTITUIDO CON HALOGENO O METIL. SON COMPUESTOS PREFERIDOS: ACIDO 3-(5-{5-[4-FENIL-5-(TRIFLUOROMETIL)-2-TIENIL]-1,2,4-OXADIAZOL-3-IL}-1H-INDOL-1-IL)PROPANOICO, ACIDO 3-[5-(5-{3-CLORO-4-[(1-METILETIL)OXI]FENIL}-1,2,4-OXADIAZOL-3-IL)-1H-INDOL-1-IL]PROPANOICO, ACIDO 3-[3-CLORO-5-(5-{3-CLORO-4-[(1-METILETIL)OXI]FENIL}-1,2,4-OXADIAZOL-3-IL)-1H-INDOL-1-IL]PROPANOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR SENSIBLE A 1-FOSFATO DE ESFINGOSINA (S1P1) SIENDO UTILES EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLE, ASMA, ARTRITIS, LUPUS ERITEMATOSO, PSORIASIS, TUMORES SOLIDOS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625647A GB0625647D0 (en) | 2006-12-21 | 2006-12-21 | Compounds |
| GB0707615A GB0707615D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081398A1 true PE20081398A1 (es) | 2008-11-19 |
Family
ID=39283563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000146A PE20121076A1 (es) | 2006-12-21 | 2008-01-02 | Composicion farmaceutica que comprende un analgesico y vitaminas |
| PE2008000023A PE20081398A1 (es) | 2006-12-21 | 2008-01-02 | Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000146A PE20121076A1 (es) | 2006-12-21 | 2008-01-02 | Composicion farmaceutica que comprende un analgesico y vitaminas |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8101775B2 (es) |
| EP (2) | EP2206710B1 (es) |
| JP (1) | JP5309034B2 (es) |
| KR (1) | KR101495927B1 (es) |
| CN (1) | CN103012390B (es) |
| AR (1) | AR064452A1 (es) |
| AT (1) | ATE509927T1 (es) |
| AU (1) | AU2007336224B2 (es) |
| BR (1) | BRPI0721127A2 (es) |
| CA (1) | CA2673468C (es) |
| CL (1) | CL2007003755A1 (es) |
| CR (2) | CR10922A (es) |
| CY (2) | CY1111702T1 (es) |
| DK (2) | DK2091949T3 (es) |
| DO (1) | DOP2009000133A (es) |
| EA (1) | EA017406B1 (es) |
| ES (1) | ES2389879T3 (es) |
| HR (2) | HRP20110456T1 (es) |
| IL (1) | IL199187A (es) |
| JO (1) | JO2701B1 (es) |
| MA (1) | MA30999B1 (es) |
| MX (1) | MX2009006882A (es) |
| MY (2) | MY148470A (es) |
| NO (1) | NO20092385L (es) |
| NZ (1) | NZ577387A (es) |
| PE (2) | PE20121076A1 (es) |
| PL (2) | PL2091949T3 (es) |
| PT (2) | PT2091949E (es) |
| SG (1) | SG177914A1 (es) |
| SI (2) | SI2091949T1 (es) |
| TW (1) | TWI393564B (es) |
| WO (1) | WO2008074821A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356221B (es) | 2006-04-03 | 2018-05-18 | Astellas Pharma Inc | Heterocompuesto. |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| JO2686B1 (en) * | 2007-04-19 | 2013-03-03 | جلاكسو جروب ليمتد | Vehicles |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| JP5837417B2 (ja) | 2008-05-14 | 2015-12-24 | ザ スクリプス リサーチ インスティテュート | スフィンゴシンリン酸受容体の新規なモジュレーター |
| WO2009151626A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| WO2009151621A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| UY31922A (es) | 2008-06-20 | 2010-01-05 | Glaxo Group Ltd | Compuestos |
| SG10201503157PA (en) * | 2008-07-23 | 2015-06-29 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| BRPI0916812B8 (pt) | 2008-07-23 | 2022-10-18 | Arena Pharm Inc | Derivados do ácido 1,2,3,4-tetra-hidrociclopenta[b]indol-3-il)acético substituído úteis no tratamento de distúrbios autoimunes e inflamatórios, seu uso, composição farmacêutica que os compreende e processo de preparação |
| PT2342205T (pt) * | 2008-08-27 | 2016-07-28 | Arena Pharm Inc | Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios |
| WO2010069949A1 (en) | 2008-12-18 | 2010-06-24 | Merck Serono S.A. | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| EP2202232A1 (en) * | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2241558A1 (en) * | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| GB0910667D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| WO2011005295A1 (en) * | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| HRP20180874T4 (hr) | 2009-11-13 | 2024-09-27 | Receptos Llc | Selektivni modulatori receptora sfingozin-1-fosfata i postupci kiralne sinteze |
| EP2513095A4 (en) * | 2009-12-18 | 2013-05-15 | Glaxo Group Ltd | OXADIAZOLSUBSTITUTED INDAZONE DERIVATIVES FOR USE AS SPHINGOSIN-1-PHOSPHATE-1 (S1P1) RECEPTOR AGONISTS |
| ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
| CN102884064B (zh) * | 2010-03-03 | 2016-01-13 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| EP2560969B1 (en) | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
| ES2548258T3 (es) | 2010-09-24 | 2015-10-15 | Bristol-Myers Squibb Company | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 |
| ES2772258T3 (es) | 2011-02-07 | 2020-07-07 | Biogen Ma Inc | Agentes moduladores de S1P |
| EP2706999B1 (en) | 2011-05-13 | 2019-08-28 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
| MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
| CA3034796A1 (en) * | 2016-07-22 | 2018-01-25 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | S1p1 agonist and application thereof |
| EP3518922A1 (en) * | 2016-09-29 | 2019-08-07 | Celgene International II Sarl | Compounds and methods for treating lupus |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| AU2018222747A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| KR102859841B1 (ko) | 2018-06-06 | 2025-09-12 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 병태의 치료 방법 |
| CN110627778B (zh) * | 2018-06-25 | 2023-01-24 | 中国科学院上海药物研究所 | 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用 |
| WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| UA129627C2 (uk) | 2019-10-31 | 2025-06-18 | Ідорсія Фармасьютікалз Лтд | Комбінація антагоніста cxcr7 з модулятором рецептора s1p1 |
| NZ789014A (en) | 2019-12-03 | 2025-07-25 | Lg Chemical Ltd | Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient |
| WO2021160680A1 (en) * | 2020-02-11 | 2021-08-19 | Syngenta Crop Protection Ag | Pesticidally active cyclic amine compounds |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3939238A1 (de) | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
| DE4002466A1 (de) | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
| US5523312A (en) | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| WO2003105771A2 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| CA2524867A1 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| CA2547198A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| CN101043887A (zh) | 2004-10-22 | 2007-09-26 | 默克公司 | 用作s1p受体激动剂的2－(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物 |
| MX2007010112A (es) | 2005-02-25 | 2007-10-12 | Ono Pharmaceutical Co | Compuesto indol y uso del mismo. |
| WO2006100633A1 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS |
| BRPI0609994A2 (pt) | 2005-04-22 | 2011-10-18 | Daiichi Sankyo Co Ltd | composto, composição medicinal e uso de um ou mais compostos ou um sal farmacologicamente aceitável dos mesmos 31/12 a61p 33/02 a61p 35/00 a61p 35/02 a61p 37/02 a61p 37/06 a61p 37/08 |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| RU2008110949A (ru) | 2005-08-23 | 2009-09-27 | Айрм Ллк (Bm) | Соединения и композиции-иммуносупрессанты |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| JP2007262009A (ja) | 2006-03-29 | 2007-10-11 | Dai Ichi Seiyaku Co Ltd | ヘテロアリール低級カルボン酸誘導体 |
| MX356221B (es) | 2006-04-03 | 2018-05-18 | Astellas Pharma Inc | Heterocompuesto. |
| BRPI0716171B8 (pt) | 2006-09-07 | 2021-05-25 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica e uso de um composto |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| JO2686B1 (en) | 2007-04-19 | 2013-03-03 | جلاكسو جروب ليمتد | Vehicles |
-
2007
- 2007-12-17 JO JO2007554A patent/JO2701B1/en active
- 2007-12-19 AT AT07857808T patent/ATE509927T1/de active
- 2007-12-19 BR BRPI0721127-9A patent/BRPI0721127A2/pt not_active IP Right Cessation
- 2007-12-19 EP EP10158582A patent/EP2206710B1/en active Active
- 2007-12-19 AU AU2007336224A patent/AU2007336224B2/en not_active Ceased
- 2007-12-19 HR HR20110456T patent/HRP20110456T1/hr unknown
- 2007-12-19 SI SI200730670T patent/SI2091949T1/sl unknown
- 2007-12-19 MY MYPI20092612A patent/MY148470A/en unknown
- 2007-12-19 KR KR1020097012841A patent/KR101495927B1/ko not_active Expired - Fee Related
- 2007-12-19 MX MX2009006882A patent/MX2009006882A/es active IP Right Grant
- 2007-12-19 NZ NZ577387A patent/NZ577387A/en not_active IP Right Cessation
- 2007-12-19 JP JP2009542043A patent/JP5309034B2/ja not_active Expired - Fee Related
- 2007-12-19 WO PCT/EP2007/064185 patent/WO2008074821A1/en not_active Ceased
- 2007-12-19 PT PT07857808T patent/PT2091949E/pt unknown
- 2007-12-19 CA CA2673468A patent/CA2673468C/en not_active Expired - Fee Related
- 2007-12-19 TW TW096148543A patent/TWI393564B/zh not_active IP Right Cessation
- 2007-12-19 PT PT10158582T patent/PT2206710E/pt unknown
- 2007-12-19 ES ES10158582T patent/ES2389879T3/es active Active
- 2007-12-19 DK DK07857808.5T patent/DK2091949T3/da active
- 2007-12-19 US US12/520,145 patent/US8101775B2/en not_active Expired - Fee Related
- 2007-12-19 PL PL07857808T patent/PL2091949T3/pl unknown
- 2007-12-19 SG SG2011095114A patent/SG177914A1/en unknown
- 2007-12-19 SI SI200731001T patent/SI2206710T1/sl unknown
- 2007-12-19 DK DK10158582.6T patent/DK2206710T3/da active
- 2007-12-19 EA EA200970612A patent/EA017406B1/ru not_active IP Right Cessation
- 2007-12-19 PL PL10158582T patent/PL2206710T3/pl unknown
- 2007-12-19 AR ARP070105729A patent/AR064452A1/es unknown
- 2007-12-19 MY MYPI2012004367A patent/MY156822A/en unknown
- 2007-12-19 CN CN201210396720.5A patent/CN103012390B/zh not_active Expired - Fee Related
- 2007-12-19 EP EP07857808A patent/EP2091949B1/en active Active
- 2007-12-20 CL CL200703755A patent/CL2007003755A1/es unknown
-
2008
- 2008-01-02 PE PE2012000146A patent/PE20121076A1/es not_active Application Discontinuation
- 2008-01-02 PE PE2008000023A patent/PE20081398A1/es not_active Application Discontinuation
-
2009
- 2009-06-04 IL IL199187A patent/IL199187A/en not_active IP Right Cessation
- 2009-06-05 DO DO2009000133A patent/DOP2009000133A/es unknown
- 2009-06-17 MA MA32003A patent/MA30999B1/fr unknown
- 2009-06-23 NO NO20092385A patent/NO20092385L/no not_active Application Discontinuation
- 2009-07-13 CR CR10922A patent/CR10922A/es unknown
-
2011
- 2011-07-19 CY CY20111100700T patent/CY1111702T1/el unknown
-
2012
- 2012-08-29 HR HRP20120685TT patent/HRP20120685T1/hr unknown
- 2012-09-20 CY CY20121100862T patent/CY1113131T1/el unknown
-
2014
- 2014-07-01 CR CR20140316A patent/CR20140316A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081398A1 (es) | Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1) | |
| PE20090150A1 (es) | Compuestos derivados de oxadiazol | |
| PE20081199A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
| PE20091339A1 (es) | Derivados de oxadiazol con actividad sobre receptores s1p1 | |
| PE20090290A1 (es) | Derivados de pirrolopiridina como inhibidores de bace | |
| ES2512727T3 (es) | Nuevos compuestos | |
| JP5301286B2 (ja) | Ｆｘ受容体を調節するための化合物及び方法 | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| TN2012000557A1 (en) | Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide | |
| PE20121474A1 (es) | Nuevos compuestos de espiropiperidina | |
| CO6260017A2 (es) | Compuestos de oxazol, oxadiazol y tiadiazol utiles para el control de nematodos | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20161396A1 (es) | Compuesto heterociclico | |
| PE20120732A1 (es) | Agonistas del receptor de esfingosina-1-fosfato | |
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| PE20091901A1 (es) | Activadores de glucoquinasa | |
| NZ593969A (en) | Pyrazine derivatives useful as inhibitors of atr kinase | |
| WO2009051956A3 (en) | Pyrazole-substituted isoxazoline insecticides | |
| NZ613234A (en) | Compositions and methods for modulating fxr | |
| RU2006129341A (ru) | Способ получения 5-хлор-n-(5s)-2-оксо-3-{4-(3-оксо-4-морфолинил)-фенил}-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида | |
| PE20021152A1 (es) | Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma | |
| PE20110906A1 (es) | Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif | |
| PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
| PE20120934A1 (es) | Piperidinas sustituidas | |
| RU2013139662A (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |